Home

John W Smither

CIK 1559583 · Chief Financial Officer · last filed 2026-09-09

John W Smither is a Chief Financial Officer who has filed 80 SEC Form 4 insider transactions across 11 companies since 2013. The most recent filing shows the insider sold $40.5K of NAMS on Sep 9, 2026. Across all open-market trades the lifetime net is −$8.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.65M

Companies

11

Total Filings

80

Lifetime Open-Market Net

-$8.71M

Filer Profile

Reported Address
C/O GENELUX CORPORATION
2625 TOWNSGATE ROAD. SUITE 230
WESTLAKE VILLAGE, CA 91361
Related Filers
Attovia Therapeutics, Inc. — 1 joint filings, latest 2026-08-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NAMS Director 8,760 $22.80 $199.7K -$40.5K 1 2026-09-09
MBX Chief Financial Officer 28,000 $59.02 $1.65M $0 1 2026-08-04
GNLX Director 91,403 $2.49 $227.6K -$53.6K 8 2026-07-02
NAMSW Director 10,360 $11.78 $122.0K $0 3 2026-01-09
ARQT Chief Financial Officer 144,185 $23.89 $3.44M -$619.5K 12 2024-02-15
Applied Molecular Transport Inc. (AMTI) Delisted Director — $0.26 — $0 4 2023-12-28
eFFECTOR Therapeutics, Inc. (EFTRW) Delisted Director 24,142 $0.00 $14 $0 5 2023-06-22
Principia Biopharma Inc. (PRNB) Delisted Director — — — $0 1 2019-02-21
Sienna Biopharmaceuticals, Inc. (SNNA) Delisted Chief Financial Officer 81,618 — — $0 3 2019-01-03
Achaogen, Inc. (AKAO) Delisted Director — — — $0 5 2018-06-07
KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted Chief Financial Officer 0 — — -$7.99M 34 2015-10-02

Recent Filings

80 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-09 NAMS Sell (S) −1,600 -$40.5K EDGAR
2026-08-04 MBX Grant (A) +28,000 $0 EDGAR
2026-07-02 GNLX Sell (S) −12,000 -$34.9K EDGAR
2026-07-01 GNLX Notice (144) −12,000 -$34.9K EDGAR
2026-06-18 GNLX Grant (A) +28,409 $0 EDGAR
2026-01-09 NAMSW Grant (A) +3,400 $0 EDGAR
2025-08-29 GNLX Grant (A) +22,283 $0 EDGAR
2025-01-08 NAMSW Grant (A) +6,960 $0 EDGAR
2024-12-31 GNLX Grant (A) — $0 EDGAR
2024-08-05 GNLX Grant (A) +39,541 $0 EDGAR
Showing 1–10 of 80
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.